Which practice should be performed during testing to ensure consent handling is correct?

Which practice should be performed during testing to ensure consent handling is correct?

• A. Only test consent in the production environment.
• B. Validate consent status as part of integration tests.
• C. Consent is not relevant to testing.
• D. Request patient consent after go-live.

Answer: (B)

What’s being tested is that consent handling is properly validated across systems during testing. In an environment where data moves between the EHR, consent management, and data recipients, the consent status must travel with the data and enforce sharing rules everywhere it goes. Integration tests simulate real data flows and verify that when a patient consents to share certain data, the permitted data is accessible and that any changes—such as withdrawal, expiration, or scope adjustments—propagate correctly and are auditable. This ensures compliance and protects patient privacy before going live. Testing only in production is unsafe and makes it hard to cover edge cases or reproduce issues without impacting real patients. Treating consent as irrelevant to testing ignores a critical control that governs who can access what data. Waiting to request consent after go-live would violate data-sharing requirements and patient rights.

What’s being tested is that consent handling is properly validated across systems during testing. In an environment where data moves between the EHR, consent management, and data recipients, the consent status must travel with the data and enforce sharing rules everywhere it goes. Integration tests simulate real data flows and verify that when a patient consents to share certain data, the permitted data is accessible and that any changes—such as withdrawal, expiration, or scope adjustments—propagate correctly and are auditable. This ensures compliance and protects patient privacy before going live.

Testing only in production is unsafe and makes it hard to cover edge cases or reproduce issues without impacting real patients. Treating consent as irrelevant to testing ignores a critical control that governs who can access what data. Waiting to request consent after go-live would violate data-sharing requirements and patient rights.